FrancophonIA/ELRC3.0 huggingface dataset:
English: EU/1/99/127/028 1 multiple dose vial, 6 injection syringes of 1 mL, 6 injection needles and 12 cleansing swabs
Maltese: EU/1/99/127/028 1 kunjett b'ħafna dożi, 6 siringi għall-injezzjoni, 6 labar għall-injezzjoni u12
English: - One mL of solution contains 10 million IU of interferon alfa-2b
Maltese: - Millilitru wieħed tas-soluzzjoni fiha 10 miljun IU ta' interferon alfa-2b
English: EU/1/99/127/015 1 single dose vial
Maltese: EU/1/99/127/015
English: Dispose of the syringe with attached needle safely in a closed container.
Maltese: Armi ssiringa u l-labar ġo kontenitur magħluq b'mod sigur.
English: This must be considered during concomitant therapy with medicinal products metabolised by this route, such as the xanthine derivatives theophylline or aminophylline.
Maltese: Dan irid ikun ikkunsidrat waqt terapija fl-istess ħin ma' prodotti mediċinali li jkunu metabolizzati minn din ir-rotta, bħal ma huma dderivattivi ta' xanthine, theophylline jew aminophylline.
English: EU/1/99/127/012 1 single dose vial, 1 injection syringe of 1 mL, 1 injection needle and 1 cleansing swab
Maltese: EU/1/99/127/012 1 kunjett b'doża waħda, 1 siringa għall-injezzjoni ta' 1 mL, 1 labra għallinjezzjoni u 1 tajjara għall-injezzjoni
English: IntronA 18 million IU/3 mL solution for injection or infusion Interferon alfa-2b
Maltese: U MNEJN GĦANDU JINGĦATA IntronA 18 miljun IU/3 mL soluzzjoni għall-injezzjoni jew infużjoni Interferon alfa-2b
English: The usual dose is 5 million IU (3 to 9 million IU) administered subcutaneously three times a week (every other day).
Maltese: Id-doża normali hi ta' 5 miljun IU (3 sa 9 miljun IU) mogħtija taħt il-ġilda tliet darbiet fil-ġimgħa (darba kull jumejn).
English: Cases of stroke (cerebrovascular events) have been reported.
Maltese: Każijiet ta' puplesija (avvenimenti ċerebrovaskulari) kienu rrappurtati.
English: EU/1/99/127/018 12 single dose vials, 12 injection syringes of 1 mL, 12 injection needles and 12 cleansing swabs
Maltese: EU/1/99/127/018 12-il kunjett b'doża waħda, 12-il siringa għall-injezzjoni ta' 1 mL, 12-il labra għallinjezzjoni u 12-il tajjara għat-tindif
English: Other CNS effects including aggressive behaviour (sometimes directed against others such as homicidal ideation), bipolar disorders, mania, confusion and alterations of mental status have been observed with alpha interferons.
Maltese: Effetti oħra fuq is-CNS li jinkludu mġiba aggressiva (kultant indirizzata lejn l-oħrajn bħal ħsibijiet dwar omiċidju), disturbi bipolari, manija, konfużjoni u tibdil fl-istat mentali dehru b'alpha interferons.
English: In adult patients receiving interferon in combination with ribavirin, the achieved sustained response rate is 47 %.
Maltese: F'pazjenti adulti li jkunu qed jirċievu interferon f'kombinazzjoni ma' ribavirin, ir-rata ta' rispons sostnut li nkisbet hija ta' 47 %.
English: EU/1/99/127/022 12 single dose vials, 12 injection syringes of 2 mL, 12 injection needles and 12 cleansing swabs
Maltese: EU/1/99/127/022 12-il kunjett b'doża waħda, 12-il siringa għall-injezzjoni ta' 2 mL, 12-il labra għallinjezzjoni u 12-il tajjara għat-tindif
English: Adjunctively with chemotherapy, interferon alfa-2b may be administered subcutaneously, at a dose of 5 million IU three times a week (every other day) for a duration of 18 months.
Maltese: Bħala żieda mal-kimoterapija, interferon alfa-2b jista' jingħata taħt il-ġilda, f'doża ta' 5 miljun IU tliet darbiet fil-ġimgħa (darba kull jumejn) għal tul ta' 18-il xahar.
English: It is thought that this process, at least in part, is responsible for the various cellular responses to interferon, including inhibition of virus replication in virus-infected cells, suppression of cell proliferation and such immunomodulating activities as enhancement of the phagocytic activity of macrophages and augmentation of the specific cytotoxicity of lymphocytes for target cells.
Maltese: Huwa maħsub li dan il-proċess huwa responsabbli, għall-inqas parzjalment, għad-diversi risponsi ċellulari għal interferon, fosthom l-inibizzjoni tar-replikazzjoni tal-virus f' ċelluli infettati minn virus, it-trażżin tal-proliferazzjoni taċ-ċelluli u attivitajiet immunomodulattivi bħal ma huma lattività fagoċitika tal-makrofaġi u ż-żieda taċ-ċitotossiċità speċifika tal-limfoċiti għaċ-ċelluli fil-mira.
English: EU/1/99/127/023 1 multiple dose vial
Maltese: EU/1/99/127/023 1 kunjett 1 b'ħafna dożi
English: Important information about some of the ingredients of IntronA This medicinal product contains less than 1 mmol sodium (23 mg) per 3 mL, i.e., essentially "sodiumfree".
Maltese: Tagħrif importanti dwar xi wħud mill-ingredjenti ta' IntronA Dan il-prodotti mediċinali fih anqas minn 1 mmol sodium (23 mg), għal kull 3 mL, i.e. jista' jitqies “mingħajr sodium”.
English: Maintenance treatment: 10 million IU/m 2, 3 times a week (every other day) injected subcutaneously (under the skin).
Maltese: Kura ta' manteniment: 10 miljun IU/m², 3 darbiet fil-ġimgħa (darba kull jumejn) injettati taħt il-ġilda.
English: EU/1/99/127/043 2 multiple dose vials, 12 injection syringes of 1 mL, 12 injection needles and 24 cleansing swabs
Maltese: EU/1/99/127/043 2 kunjetti b'ħafna dożi, 12-il siringa għall-injezzjoni, 12-il labra għall-injezzjoni u 24 tajjara għall-injezzjoni
English: Check with your doctor immediately if any of the following side effects occur: - chest pain or persistent and severe cough; irregular or rapid heartbeat; shortness of breath, confusion, difficulty remaining alert, numbness or tingling sensation or pain in hands or feet; seizure (convulsions); trouble sleeping, thinking or concentrating; altered mental state; suicidal thoughts, suicide attempt, changed behaviour or aggressive behaviour (sometimes directed against others), hallucinations; severe stomach pain; black or tar like stools; blood in stool or urine, severe nosebleed; waxy pallor, high sugar level in blood, fever or chills beginning after a few weeks of treatment, lower back or side pain, difficult urination, problems with your eyes or your eyesight or hearing, loss of hearing, severe or painful reddening or sores on your skin or mucous membrane.
Maltese: uġigħ fis-sider jew sogħla qawwija u persistenti; taħbit tal-qalb irregolari jew mgħaġġel; qtugħ ta' nifs, konfużjoni, tbatija biex toqgħod attent, sensazzjoni ta' tnemnim jew tingiż fl-idejn jew fir-riġlejn; aċċessjoni (konvulżjonijiet); tbati biex torqod, taħseb jew tikkonċentra; stat mentali mibdul; ħsibijiet dwar suwiċidju, attentati ta' suwiċidju, imġiba aggressiva jew mibdula (kultant indirizzata lejn l-oħrajn); alluċinazzjonijiet; uġigħ sever fl-istonku; ippurgar iswed jew jixbah lill-qatran; demm fl-ippurgar jew fl-awrina, tinfaraġ bil-qawwi; issir isfar, livell għoli ta' zokkor fid-demm, deni jew tkexkix ta' bard li jibdew wara ftit ġimgħat ta' kura, uġigħ fin-naħa t'isfel tad-dahar jew fil-ġenb, diffikultà biex tagħmel l-awrina, problemi fl-għajnejn jew fil-vista jew fis-smigħ, telf tas-smigħ, ħmura qawwija jew li tweġġa' jew feriti fuq il-ġilda jew fuq il membrana mukuża.
English: One vial contains 5 million IU of interferon alfa-2b in 0.5 mL of solution.
Maltese: DIKJARAZZJONI TAS-SUSTANZA(I) ATTIVA(I) Kunjett wieħed fih 5 miljun IU ta' interferon alfa-2b f'soluzzjoni ta' 0.5 mL.
English: Preclinical juvenile toxicity results have demonstrated a minor, dose-related decrease in overall growth in neonatal rats dosed with ribavirin (see section 5.3 of Rebetol SPC if IntronA is to be administered in combination with ribavirin).
Maltese: Disturbi tas-snien u disturbi perjodentali, li jistgħu jwasslu għal telf tas-snien, kienu rrappurtati f'pazjenti li kienu qed jirċievu terapija kombinata ta' IntronA u ribavirin.
English: 5 million IU/0.5 mL solution for injection or infusion 1 single dose vial
Maltese: 5 miljun IU/0.5 mL soluzzjoni għall-injezzjoni jew infużjoni 1 kunjett b'doża waħda
English: Caution must be exercised when administering IntronA in combination with other potentially myelosuppressive agents.
Maltese: Għandu jkun hemm attenzjoni meta jingħata IntronA flimkien ma' sustanzi oħra potenzjalement majelosoppressivi.
English: In a large study, 1,071 patients were enrolled after treatment in a prior non-pegylated interferon alfa2b or non-pegylated interferon alfa-2b/ribavirin study to evaluate the durability of sustained virologic response and assess the impact of continued viral negativity on clinical outcomes.
Maltese: Fi studju kbir, 1,071 pazjent ġew irreġistrati wara kura fi studju b'interferon alfa-2b mhux pegilat jew b'interferon alfa-2b mhux pegilat/ribavirin sabiex jiġi evalwat kemm idum ir-rispons viroloġiku sostnut u jiġi evalwat l-impatt ta' negattività virali kontinwa fuq ir-riżultati kliniċi.
English: Combination therapy with ribavirin Ribavirin therapy is contraindicated in women who are pregnant.
Maltese: Terapija b'ribavirin hija kontraindikata f'nisa li huma tqal.
English: IntronA 18 MIU
Maltese: INFORMAZZJONI BIL-BRAILLE IntronA 18 MIU
English: No case of overdose has been reported that has led to acute clinical manifestations.
Maltese: Ma kien irrappurtat l-ebda każ ta' doża eċċessiva li wassal għal manifestazzjonijiet kliniċi akuti.
English: 2 multiple dose vials, 12 injection syringes of 1 mL, 12 injection needles and 24 cleansing swabs 2 multiple dose vials, 12 injection syringes with attached needle and needle protection device of 1 mL and 24 cleansing swabs
Maltese: 2 kunjetti b'ħafna dożi, 12-il siringa għall-injezzjoni, 12-il labra għall-injezzjoniu 24 tajjara għat-tindif 2 kunjetti b'ħafna dożi, 12-il siringa għall-injezzjoni b'labra mqabbda u apparat ta' protezzjoni tallabra ta' 1 mL u 24 tajjara għat-tindif
English: Patients treated with IntronA and ribavirin combination therapy and zidovudine could be at increased risk of developing anaemia.
Maltese: Pazjenti kkurati b'terapija kombinata ta' IntronA u ribavirin u zidovudine jistgħu jkunu f'riskju akbar li jiżviluppaw anemija.
English: §, retinopathies (including macular oedema), retinal artery or vein obstruction
Maltese: Esperjenzi avversi inkluż titwil tal-markaturi tal-koagulazzjoni u anormalitajiet tal-fwied
English: §, influenza-like symptoms
Maltese: Disturbi psikjatriċi§
English: Pack of 12 vials, 72 injection syringes of 1 mL, 72 injection needles and 144 cleansing swabs Pack of 12 vials, 72 injection syringes with attached needle and needle protection device of 1 mL and 144 cleansing swabs
Maltese: Pakkett ta' 12-il kunjett, 72 siringa tal-injezzjoni ta' 1 mL, 72 labra għall-injezzjoni u 144 tajjara għat-tindif
English: 3 million IU/0.5 mL solution for injection or infusion 1 single dose vial
Maltese: 3 miljun IU/0.5 mL soluzzjoni għall-injezzjoni jew infużjoni 1 kunjett b'doża waħda
English: EU/1/99/127/024 1 multiple dose vial 6 injection syringes of 1 mL, 6 injection needles and 12 cleansing swabs
Maltese: EU/1/99/127/024 1 kunjett 1 b'ħafna dożi, 6 siringi għall-injezzjoni ta' 1 mL, 6 labar għall-injezzjoni u12-il tajjara għall-injezzjoni
English: Important information about some of the ingredients of IntronA This medicinal product contains less than 1 mmol sodium (23 mg) per 1 mL, i.e., essentially "sodiumfree".
Maltese: Tagħrif importanti dwar xi wħud mill-ingredjenti ta' IntronA Dan il-prodotti mediċinali fih anqas minn 1 mmol sodium (23 mg), għal kull 1 mL, i.e. jista' jitqies “mingħajr sodium”.
English: (affects 1 to 10 users in 100) Uncommon (affects 1 to 10 users in 1,000) Rare
Maltese: (jaffettwaw 1 sa 10 f'100 li jużawh) Mhux komuni (jaffettwaw 1 sa 10 f'1,000 li jużawh)
English: 2 multiple dose vials, 12 injection syringes of 1 mL, 12 injection needles and 24 cleansing swabs 2 multiple dose vial, 12 injection syringes with attached needle and needle protection device of 1 mL and 24 cleansing swabs
Maltese: 2 kunjetti b'ħafna dożi, 12-il siringa għall-injezzjoni ta' 1 mL, 12-il labra għall-injezzjoni u 24 tajjara għat-tindif
English: IntronA must be used with caution in fertile men.
Maltese: IntronA għandu jintuża b'attenzjoni f'irġiel fertili.
English: The adverse reactions listed in Table 2 are based on experience from the two multicentre children and adolescent clinical trials.
Maltese: Ir-reazzjonijiet avversi elenkati f'Tabella 2 huma bbażati fuq esperjenza minn żewġ provi kliniċi multiċentriċi fuq tfal u adolexxenti.
English: and 24 cleansing swabs - Pack of 12 vials - Pack of 12 vials, 72 injection syringes of 1 mL, 72 injection needles and 144 cleansing swabs - Pack of 12 vials, 72 injection syringes with attached needle and needle protection device of
Maltese: 144 tajjara għat-tindif - Pakkett b'12-il kunjett, 72 siringa għall-injezzjoni b'labra mqabbda u apparat ta' protezzjoni tal labra ta' 1 mL u 144 tajjara għat-tindif
English: Duration of treatment for children and adolescents
Maltese: Tul tal-kura għal tfal u adolexxenti
English: All patients were followed for an additional 6 months after the end of treatment for the determination of sustained virologic response.
Maltese: Il-pazjenti kollha kienu segwiti għal 6 xhur addizzjonali wara t-tmiem tal-kura biex ikun determinat ir-rispons viroloġiku sostnut.
English: Decreased serum estradiol and progesterone concentrations have been reported in women treated with human leukocyte interferon.
Maltese: Konċentrazzjonijiet imnaqqsa ta' estradiol u ta' progesterone fis-serum kienu rrappurtati fin-nisa kkurati b'interferon tal-lewkoċiti tal-bniedem.
English: Growth and development (children and adolescents):
Maltese: Popolazzjoni ta' tfal u adolexxenti:
English: Pack of 2 vials, 12 injection syringes of 1 mL, 12 injection needles and 24 cleansing swabs Pack of 2 vials, 12 injection syringes with attached needle and needle protection device of 1 mL and 24 cleansing swabs
Maltese: Pakkett ta' 2 kunjetti, 12-il siringa għall-injezzjoni ta' 1 mL, 12-il labra għall-injezzjoni u 24 tajjara għat-tindif
English: EU/1/99/127/014 12 single dose vials, 12 injection syringes of 1 mL, 12 injection needles and 12 cleansing swabs
Maltese: EU/1/99/127/014 12-il kunjett b'doża waħda, 12-il siringa għall-injezzjoni ta' 1 mL, 12-il labra għallinjezzjoni u 12-il tajjara għat-tindif
English: IntronA should be given alone mainly in case of intolerance or contraindication to ribavirin.
Maltese: IntronA għandu jingħata waħdu l-aktar f'każijiet ta' intolleranza jew ta' kontraindikazzjoni għal ribavirin.
English: Any thyroid abnormality detected at that time must be treated with conventional therapy.
Maltese: Kwalunkwe anormalità tat-tirojde li tinstab f'dak listadju trid tkun ikkurata b'terapija konvenzjonali.
English: 462 patients completed at least 5 years of long-term follow-up and only 12 sustained responders' out of 492 relapsed during this study.
Maltese: 462 pazjent lestew mill-anqas 5 snin ta' follow-up fit-tul u 12 biss minn dawk li wrew rispons sostnut minn 492 pazjent irkadew waqt dan l-istudju.
English: High doses of other forms of interferons alpha and beta are known to produce doserelated anovulatory and abortifacient effects in rhesus monkeys.
Maltese: Dożi għoljin ta' forom oħra ta' interferoni alpha u beta huma magħrufa li jipproduċu effetti relatati mad-doża li jwaqqfu l-ovulazzjoni u li jwasslu għal abort fix-xadini tar-razza rhesus.
English: Final adult height was available for 14 of those children and demonstrated that 12 continued to show height deficits > 15 percentiles, 10 to 12 years after the end of treatment.
Maltese: It-tul finali bħala adulti kien disponibbli għal 14 minn dawk it-tfal u wera li 12 komplew juru defiċjenzi fit-tul > 15-il punt perċentwali, 10 sa 12-il sena wara t-tmiem tal-kura.
English: If you have them, you may have had a serious allergic reaction to IntronA.
Maltese: Jekk ikollok minnhom, jista' jkun li kellek reazzjoni allerġika serja għal IntronA.
English: Following a referral procedure (EMEA/V/A/088)
Maltese: Wara proċedura ta' riferiment (EMEA/V/A/088)
English: Rivium Westlaan 74 2909 LD Capelle a/d Ijssel
Maltese: Westlaan 74 2909 LD Capelle a/d Ijssel
English: Andrew Street London, EC4A 3AE United Kingdom
Maltese: London, EC4A 3AE United Kingdom
English: Zoetis UK Limited 5th Floor, 6 St.
Maltese: Ir-Renju Unit Zoetis UK Limited 5th Floor, 6 St.
English: Postępu 17 B 02-676 Warszawa Poland
Maltese: 02-676 Warszawa Poland
English: nv Hoge Mauw 900 2370 Arendonk Belgium
Maltese: V.M.D. nv Hoge Mauw 900 2370 Arendonk Belgium
English: Denmark Pfizer Oy Animal Health
Maltese: Pfizer Oy Animal Health
English: Lannelongue 75014 Paris France
Maltese: Lannelongue 75014
English: Belgium KELA N.V. Sint Lenaartseweg
Maltese: Il-Belġju KELA N.V. Sint Lenaartseweg
English: Zoetis Netherlands Holdings B.V.
Maltese: Il-Kroazja Zoetis Netherlands Holdings B.V.
English: Kepro B.V. Maagdenburgstraat
Maltese: Il-Bulgarija Kepro B.V. Maagdenburgstraat
English: Zone D'Activites Du Bois De Teillay 35150 Janze France
Maltese: Zone D'Activites Du Bois De Teillay 35150
English: Via Andrea Doria, 41 M
Maltese: Zoetis Italia S.r.l. Via Andrea Doria, 41 M
English: Vet Consulting d.o.o.
Maltese: Il-Kroazja Vet Consulting d.o.o.
English: Germany Kon-Pharma GmbH Senator-Bauer-Str.
Maltese: Il-Ġermanja Kon-Pharma GmbH Senator-Bauer-Str.
English: FI-003300 Helsinki Finland
Maltese: FI-003300
English: The Commission Decision C(2014)5053 was issued on 11 July 2014.
Maltese: Id-Deċiżjoni talKummissjoni C(2014)5053 inħarġet fil-11 ta' Lulju 2014.
English: Add, to all products: 12.
Maltese: Żid, għall-prodotti kollha: 12.
English: Ramsgate Road Sandwich, Kent CT13 9NJ
Maltese: Ir-Rumanija Pfizer Animal Health MA EEIG Ramsgate Road Sandwich, Kent CT13 9NJ
English: CVMP reflection paper on the use of macrolides, lincosamides and streptogramins (MLS) in food-producing animals in the European Union: development of resistance and impact on human and animal health (EMA/CVMP/SAGAM/741087/2009)http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/11/WC500118230.pdf CVMP reflection paper on use of pleuromutilins in food-producing animals in the European Union: development of resistance and impact on human and animal health (EMA/CVMP/AWP/119489/2012)http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/11/WC500154734.pdf
Maltese: CVMP reflection paper on the use of macrolides, lincosamides and streptogramins (MLS) in food-producing animals in the European Union: development of resistance and impact on human and animal health (EMA/CVMP/SAGAM/741087/2009)http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/11/WC500118230.pdf CVMP reflection paper on use of pleuromutilins in food-producing animals in the European Union: development of resistance and impact on human and animal health (EMA/CVMP/AWP/119489/2012)http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/11/WC500154734.pdf minn L. intracellularis, u patoġeni enteriċi assoċjati (E. Coli)) b'doża ta' 3.33 mg lincomycin u 6.67 mg spectinomycin/kg tal-piż tal-ġisem/jum għal 7 ijiem fl-ilma tax-xorb, approvata waqt il-proċedura ta' riferiment skont l-Artikolu 34 (EMEA/V/A/088) għal Linco-Spectin 100, hija ġustifikata.
English: de Europa, 20B
Maltese: Zoetis Spain, S.L. Avda. de Europa, 20B
English: nv Hoge Mauw 900
Maltese: Il-Belġju V.M.D. nv Hoge Mauw 900
English: Germany Zoetis Deutschland GmbH
Maltese: Il-Ġermanja Zoetis Deutschland GmbH
English: Lincomycin is a lincosamide antibiotic derived from Streptomyces lincolnensis which inhibits protein synthesis.
Maltese: Lincomycin huwa antibijotiku linkosamidi derivat minn Streptomyces lincolnensis li jinibixxi s-sintesi tal-proteini.
English: Zoetis Österreich GmbH
Maltese: L-Awstrija Zoetis Österreich GmbH
English: MICOSPECTONE plv.
Maltese: MICOSPECTONE plv. sol.
English: Lithuania Bela-Pharm GmbH & Co.KG
Maltese: Il-Litwanja Bela-Pharm GmbH & Co.KG
English: Lincomycin 222 Spectinomycin 444 WSP
Maltese: Lincomycin 222 Spectinomycin 444
English: Via Emilia, 285 40064 Ozzano Emilia (BO) Italy
Maltese: Via Emilia, 285 40064
English: CONCENTRAT V061 LINCOMYCINE 4.4 SPECTINOMYCINE 4.4 PORC
Maltese: CONCENTRAT V061 LINCOMYCINE 4.4
English: LINCOTRIMEX-PREMIX Lincomycin and Spectinomycin
Maltese: LINCOTRIMEX-PREMIX Lincomycin u Spectinomycin
English: Spectinomycin is also active against Salmonella spp., and both compounds are active against Campylobacter spp.
Maltese: Spectinomycin huwa attiv ukoll kontra s-Salmonella spp., u ż-żewġ komposti huma attivi kontra l-Campylobacter spp.
English: Germany Bela-Pharm GmbH & Co.KG
Maltese: Il-Ġermanja Bela-Pharm GmbH & Co.KG
English: Pleuromutilins also share with lincosamides overlapping binding sites at the ribosomal peptidyl transferase center, and multi-resistant strains (to pleuromutilins, macrolides and lincosamides) have arisen.
Maltese: Il-plewromutilini jikkondividu wkoll mallinkosamidi, siti ta' twaħħil komuni fiċ-ċentru tal-peptidyl transferase ribosomali, u żviluppaw razez multireżistenti (għall-plewromutilini, makrolidi u linkosamidi).
English: Pigs: 3.33 mg lincomycin and 6.67 mg spectinomycin/kg bw/day, for 7 days.
Maltese: Ħnieżer: 3.33 mg lincomycin u 6.67 mg spectinomycin/kg tal-piż tal-ġisem/jum, għal 7 ijiem.
English: Linco-Spectin 22 + 22 Lincomycin and Spectinomycin
Maltese: Linco-Spectin 22 + 22 Lincomycin u Spectinomycin
English: Germany Pharmacia GmbH Linkstr.
Maltese: Il-Ġermanja Pharmacia GmbH Linkstr. 10
English: When considering lincomycin in vitro susceptibility data against B. hyodysenteriae, even if differences occur between geographical areas, and variability arises from the absence of standardised testing methodology, it appears clearly that the minimum inhibitory concentration (MIC) range is broad and http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/veterinary/referrals/LincoSpectin_100_and_associated_names/vet_referral_000097.jsp&mid=WC0b01ac05805c5170
Maltese: Meta titqies id-data dwar is-suxxettibbiltà in vitro ta' lincomycin kontra l-B. hyodysenteriae, anki jekk ikun hemm differenzi bejn żoni ġeografiċi, u tinħoloq varjabilità minħabba n-nuqqas ta' metodoloġija standardizzata tal-ittestjar, jidher b'mod ċar li l-medda tal-konċentrazzjoni inibitorja minima (MIC) hija http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/veterinary/referrals/LincoSpectin_100_and_associated_names/vet_referral_000097.jsp&mid=WC0b01ac05805c5170
English: It is generally considered that the resistance status against tylosin closely follows that for lincomycin because of cross-resistance (see e.g. the CVMP reflection paper (EMA/CVMP/SAGAM/741087/2009))
Maltese: Ġeneralment huwa meqjus li l-istatus tar-reżistenza kontra tylosin isegwi mill-qrib dak għal-lincomycin minħabba r-reżistenza inkroċjata (ara pereżempju ddokument ta' riflessjoni tas-CVMP (EMA/CVMP/SAGAM/741087/2009))
English: Chickens Oral
Maltese: Tiġieġ Orali
English: Pigs, chickens (broilers)
Maltese: Ħnieżer, tiġieġ (brojlers)
English: PM 27 LINCOMYCINE 4.4 SPECTINOMYCINE 4.4 PORC
Maltese: PM 27 LINCOMYCINE 4.4
English: Chickens: 16.65 mg lincomycin and 33.35 mg spectinomycin/kg bw/day, for 7 days.
Maltese: Tiġieġ: 16.65 mg lincomycin u 33.35 mg spectinomycin/kg tal-piż tal-ġisem/jum, għal 7 ijiem.
English: It appears that currently pleuromutilins still constitute an effective alternative for the treatment of the disease, although MIC increases, deemed as alarming, have been detected in several surveys (see CVMP reflection paper (EMA/CVMP/AWP/119489/2012))
Maltese: Jidher li attwalment il-plewromutilini għadhom jikkostitwixxu alternattiva effettiva għat-trattament talmarda, għalkemm f'diversi dundjani nstabu żidiet fil-MIC, meqjusa bħala allarmanti (ara d-dokument ta' riflessjoni tas-CVMP (EMA/CVMP/AWP/119489/2012))
English: Spectinomycin is active against avian E. coli, with observed rates of in vitro resistance of less than 20%.
Maltese: Spectinomycin huwa attiv kontra l-E. coli fit-tjur, b'rati osservati ta' reżistenza in vitro ta' anqas minn 20%.
English: In vitro studies as well as clinical efficacy data show that the lincomycin-spectinomycin combination is active against Lawsonia intracellularis.
Maltese: Studji in vitro kif ukoll data dwar l-effikaċja klinika juru li l-kombinazzjoni lincomycin-spectinomycin hija attiva kontra Lawsonia intracellularis.